Bateman Horne Center Deepens the Science Behind Oxaloacetate for ME/CFS and Long COVID

The journey toward effective treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID has long been hindered by a lack of objective measurement and translational research grounded in the real-world experience of patients.

The work of the Bateman Horne Center stands out as a beacon of evidence-based hope. This U.S. based research and clinical center is globally recognized for advancing science and care for the millions suffering with ME/CFS.

Two of the Bateman Horne Center’s recent publications highlight exciting new clinical data on oxaloacetate, a key compound under study for improving fatigue and cognition in ME/CFS available as Oxaloacetate CFS.

Understanding the Potential of Oxaloacetate for Long COVID and ME/CFS
In a 2025 forum, Dr. Suzanne Vernon and Jennifer Bell, FNP-C from Bateman Horne Center unpack findings from the REGAIN trial, a randomized, placebo-controlled study examining oxaloacetate’s impact on fatigue and cognition in Long COVID.

Over the course of the 6-week trial, participants taking Oxaloacetate CFS experienced:

• Significant improvements in cognitive function, including faster reaction times, increased cognitive efficiency, and improved accuracy in tasks requiring focus and decision-making.
  
  

• Significant reductions in symptom burden, as measured by the DePaul Symptom Questionnaire–Short Form (DSQ‑SF), with benefits emerging as early as Day 21 of Oxaloacetate therapy.
  
  

Deep Dive: Oxaloacetate for Fatigue Reduction
Bateman Horne Center’s RESTORE ME trial—a 90-day double-blind, placebo-controlled study tested 2,000 mg/day of oxaloacetate in 82 adults with ME/CFS. Results from this study include:

• A significant reduction in fatigue by an average of 25 to 35%
  

• Improvements in both mental and physical fatigue
  

• 40.5% of the oxaloacetate group classified as "enhanced responders," with an average fatigue reduction of 63%

Why the Bateman Horne Center’s Research Matters

The Bateman Horne Center is an exemplary treatment clinic and research hub combining data science, wearable technology, and compassionate clinical care for ME/CFS and Long COVID.

Founded by Dr. Lucinda Bateman, a physician who helped establish the 2015 National Academies diagnostic criteria for ME/CFS, Bateman Horne Center unites rigorous clinical trials with patient-reported outcomes and objective measures such as cognitive testing and daily activity tracking.

Read the full data from all Oxaloacetate CFS clinical trials here and review frequently asked questions here.